Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 6;10:1272728. doi: 10.3389/fnut.2023.1272728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Ohara, Suda, Kohya, Sasaki, Yoda, Yoshida, Fu, Yang, Hosoda, Maehara, Ohnishi, Tokuchi, Kitagataya, Kawagishi, Nakai, Sho, Natsuizaka, Ogawa and Sakamoto.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Survival rates stratified according to BCLC class. (A) Among patients with BCLC class 0 or A, Kaplan–Meier analysis is performed to stratify patients with and without muscle atrophy and high SAT radiodensity. The median overall survival is 1.80 years in patients with both muscle atrophy and high SAT radiodensity and not reached in the other patients. Patients with muscle atrophy and with high SAT radiodensity have a poorer prognosis than the other patients (log-rank p-value <0.001; crude Cox regression HR: 4.51, 95% CI: 1.72–11.85). (B) Among patients with BCLC class B, C, or D, Kaplan–Meier analysis was performed to stratify patients with and without muscle atrophy and high SAT radiodensity. The median overall survival is 0.40 years in patients with both muscle atrophy and high SAT radiodensity and 2.18 years in the other patients. Patients with both muscle atrophy and high SAT radiodensity have a poorer prognosis than the other patients (log-rank p-value <0.001; crude Cox regression HR: 5.36, 95% CI: 2.34–12.28). CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; SAT, subcutaneous adipose tissue.

HHS Vulnerability Disclosure